Healthcare Industry News: Mylan
News Release - July 6, 2016
Mylan Launches Generic Fenoglide(R) TabletsHERTFORDSHIRE, England and PITTSBURGH, July 6, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's FenoglideŽ. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Fenofibrate Tablets USP, 40 mg and 120 mg, had U.S. sales of approximately $28.6 million for the 12 months ending April 30, 2016, according to IMS Health.
Currently, Mylan has 246 ANDAs pending FDA approval representing $107.4 billion in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $37.2 billion in annual brand sales, for the 12 months ending December 31, 2015, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid(R) SoluTab Delayed-Release Orally Disintegrating Tablets